Journal
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 15
Volume 15, Issue -, Pages 371-394Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-genom-091212-153527
Keywords
nonsense suppression therapy; premature termination codons; nonsense mutation; readthrough
Categories
Funding
- NINDS NIH HHS [R21 NS090928] Funding Source: Medline
Ask authors/readers for more resources
Nonsense suppression therapy encompasses approaches aimed at suppressing translation termination at in-frame premature termination codons (PTCs, also known as nonsense mutations) to restore deficient protein function. In this review, we examine the current status of PTC suppression as a therapy for genetic diseases caused by nonsense mutations. We discuss what is currently known about the mechanism of PTC suppression as well as therapeutic approaches under development to suppress PTCs. The approaches considered include readthrough drugs, suppressor tRNAs, PTC pseudouridylation, and inhibition of nonsense-mediated mRNA decay. We also discuss the barriers that currently limit the clinical application of nonsense suppression therapy and suggest how some of these difficulties may be overcome. Finally, we consider how PTC suppression may play a role in the clinical treatment of genetic diseases caused by nonsense mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available